Tags

Type your tag names separated by a space and hit enter

Genetic Protection Modifications: Moving Beyond the Binary Distinction Between Therapy and Enhancement for Human Genome Editing.
CRISPR J. 2019 12; 2(6):362-369.CJ

Abstract

The current debate and policy surrounding the use of genome editing in humans typically relies on a binary distinction between therapy and human enhancement. Here, we argue that this dichotomy fails to take into account perhaps the most significant potential uses of CRISPR-Cas9 genome editing in humans. We argue that genetic treatment of sporadic Alzheimer's disease, breast and ovarian cancer predisposing BRCA1/2 mutations, and the introduction of human immunodeficiency virus resistance in humans should be considered within a new category of genetic protection treatments. We suggest that if this category is not introduced, life-altering research might be unnecessarily limited by current or future policy. Otherwise ad hoc decisions might be made, which introduce a risk of unforeseen moral costs, and might overlook or fail to address some important opportunities.

Authors+Show Affiliations

Department of Food and Resource Economics, Aarhus University, Aarhus, Denmark.Department of Veterinary and Animal Sciences, University of Copenhagen, Frederiksberg, Denmark.Department of Food and Resource Economics, Aarhus University, Aarhus, Denmark.Department of Bioneer A/S, Hørsholm, Denmark.Department of Veterinary and Animal Sciences, University of Copenhagen, Frederiksberg, Denmark.Department of Lars Bolund Institute of Regenerative Medicine, BGI-Shenzhen, Shenzhen, PR China. Department of Department of Biomedicine, Aarhus University, Aarhus, Denmark.Department of Veterinary and Animal Sciences, University of Copenhagen, Frederiksberg, Denmark.Department of Food and Resource Economics, Aarhus University, Aarhus, Denmark. Department of Veterinary and Animal Sciences, University of Copenhagen, Frederiksberg, Denmark.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

31860350

Citation

Mikkelsen, Rasmus Bjerregaard, et al. "Genetic Protection Modifications: Moving Beyond the Binary Distinction Between Therapy and Enhancement for Human Genome Editing." The CRISPR Journal, vol. 2, no. 6, 2019, pp. 362-369.
Mikkelsen RB, Frederiksen HRS, Gjerris M, et al. Genetic Protection Modifications: Moving Beyond the Binary Distinction Between Therapy and Enhancement for Human Genome Editing. CRISPR J. 2019;2(6):362-369.
Mikkelsen, R. B., Frederiksen, H. R. S., Gjerris, M., Holst, B., Hyttel, P., Luo, Y., Freude, K., & Sandøe, P. (2019). Genetic Protection Modifications: Moving Beyond the Binary Distinction Between Therapy and Enhancement for Human Genome Editing. The CRISPR Journal, 2(6), 362-369. https://doi.org/10.1089/crispr.2019.0024
Mikkelsen RB, et al. Genetic Protection Modifications: Moving Beyond the Binary Distinction Between Therapy and Enhancement for Human Genome Editing. CRISPR J. 2019;2(6):362-369. PubMed PMID: 31860350.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Genetic Protection Modifications: Moving Beyond the Binary Distinction Between Therapy and Enhancement for Human Genome Editing. AU - Mikkelsen,Rasmus Bjerregaard, AU - Frederiksen,Henriette Reventlow S, AU - Gjerris,Mickey, AU - Holst,Bjørn, AU - Hyttel,Poul, AU - Luo,Yonglun, AU - Freude,Kristine, AU - Sandøe,Peter, PY - 2019/12/21/entrez PY - 2019/12/21/pubmed PY - 2020/7/21/medline SP - 362 EP - 369 JF - The CRISPR journal JO - CRISPR J VL - 2 IS - 6 N2 - The current debate and policy surrounding the use of genome editing in humans typically relies on a binary distinction between therapy and human enhancement. Here, we argue that this dichotomy fails to take into account perhaps the most significant potential uses of CRISPR-Cas9 genome editing in humans. We argue that genetic treatment of sporadic Alzheimer's disease, breast and ovarian cancer predisposing BRCA1/2 mutations, and the introduction of human immunodeficiency virus resistance in humans should be considered within a new category of genetic protection treatments. We suggest that if this category is not introduced, life-altering research might be unnecessarily limited by current or future policy. Otherwise ad hoc decisions might be made, which introduce a risk of unforeseen moral costs, and might overlook or fail to address some important opportunities. SN - 2573-1602 UR - https://www.unboundmedicine.com/medline/citation/31860350/Genetic_Protection_Modifications:_Moving_Beyond_the_Binary_Distinction_Between_Therapy_and_Enhancement_for_Human_Genome_Editing_ L2 - https://www.liebertpub.com/doi/10.1089/crispr.2019.0024?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -